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Abstract
Background: Familial hypercholesterolemia is a human monogenic disease caused by population-
specific mutations in the low density lipoprotein (LDL) receptor gene. Despite thirteen different
mutations of the LDL receptor gene were reported from Russia prior to 2003, the whole spectrum
of disease-causing gene alterations in this country is poorly known and requires further
investigation provided by the current study.
Methods: Forty-five patients with clinical diagnosis of FH were tested for the apolipoprotein B
(apoB) mutation R3500Q by restriction fragment length analysis. After exclusion of R3500Q
mutation high-sensitive fluorescent single-strand conformation polymorphism (SSCP) analysis and
automatic DNA sequencing were used to search for mutations in the LDL receptor gene.
Results: We found twenty one rare sequence variations of the LDL receptor gene. Nineteen were
probably pathogenic mutations, and two (P518P, T705I) were considered as neutral ones. Among
the mutations likely to be pathogenic, eight were novel (c.670-671insG, C249X, c.936-940del5,
c.1291-1331del41, W422X, c.1855-1856insA, D601N, C646S), and eleven (Q12X, IVS3+1G>A,
c.651-653del3, E207X, c.925-931del7, C308Y, L380H, c.1302delG, IVS9+1G>A, V776M, V806I)
have already been described in other populations. None of the patients had the R3500Q mutation
in the apoB gene.
Conclusions: Nineteen pathogenic mutations in the LDL receptor gene in 23 probands were
identified. Two mutations c.925-931del7 and L380H are shared by St.-Petersburg population with
neighbouring Finland and several other mutations with Norway, Sweden or Denmark, i.e. countries
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from the Baltic Sea region. Only four mutations (c.313+1G>A, c.651-653del3, C308Y and W422X)
were recurrent as all those were found in two unrelated families. By this study the number of
known mutations in the LDL receptor gene in St.-Petersburg area was increased nearly threefold.
Analysis of all 34 low density lipoprotein receptor gene mutations found in St.-Petersburg argues
against strong founder effect in Russian familial hypercholesterolemia.
Background
Familial hypercholesterolemia (FH) (OMIM #143890) is
one of the most common monogenic human diseases. It
is inherited as an autosomal dominant trait with the prev-
alence of the heterozygous form conventionally consid-
ered to be about 1 of 500 in most populations [1].
Elevated blood serum cholesterol is due to impaired
removal of low-density lipoproteins (LDL) from blood by
LDL receptors, and it is associated with early onset coro-
nary artery disease and myocardial infarction. Impair-
ment of LDL receptor function usually results either from
the absence or deficiency of the LDL receptor (OMIM
*606945) itself or from a common mutation (R3500Q)
in the gene of the receptor's ligand, apolipoprotein B
(OMIM +107730) causing type B of the autosomal domi-
nant hypercholesterolemia (OMIM #144010) [2]. Fur-
thermore, a third type of monogenic autosomal dominant
hypercholesterolemia (OMIM #603776) is due to the
recently discovered defects in the proprotein convertase
PCSK9 gene (OMIM *607786) [3]. A form of recessively
inherited hypercholesterolemia (OMIM #603813) has a
prevalence of less than 1:10 000000 and is due to defects
in the LDL receptor adaptive protein ARH (OMIM
*605747) [4,5]. Even though many forms of monogenic
hypercholesterolemia are known, only apoB gene and
LDL receptor gene variations seem to contribute signifi-
cantly to the CHD morbidity in most populations [6].
The spectrum of LDL receptor mutations varies between
different human populations and more than 900 muta-
tions in the LDL receptor gene have been characterized
worldwide [7-9]. A recent review [9] shows a clear differ-
ence in the LDL receptor gene mutations spectra for West-
ern European countries, but this review gives nearly no
data on the genetics of FH in the Eastern European coun-
tries and Russia. However, many mutations were
described from Poland [10] and Bulgaria [11] and already
thirteen different LDL receptor gene mutations have been
published from the Russian population prior to 2003
[12]. In the present research we expand the study of the
molecular genetic basis for FH in St.-Petersburg known to
be the most well studied region of Russia in respect to FH-
causing mutations and report 21 mutations, previously
unknown in Russia.
Methods
Patients
Patients with FH were recruited from two lipid clinics of
St.-Petersburg, namely Institute of Human Brain and
Institute of Experimental Medicine. The clinical diagnosis
of familial hypercholesterolemia was based on the follow-
ing criteria: highly elevated plasma total cholesterol and
LDL-cholesterol, presence of tendon xanthomata, corneal
arcus or both, and positive family history of myocardial
infarction and hypercholesterolemia with at least one
first-degree relative affected. Forty-five probands fulfilling
at least two of three criteria listed above were selected for
the study. Full data of patients including their lipid data
are given in the Discussion section (see Table 2).
Informed consent was obtained in each case for DNA test-
ing procedures.
Biochemical procedures
Genomic DNA was extracted from blood white cells using
a standard method [13]. The patients were initially tested
for the apoB mutation R3500Q by restriction fragment
length analysis [14]. Exons of the LDL receptor gene were
then amplified [15], and PCR products were subjected to
gel-electrophoresis followed by ethidium bromide or sil-
ver staining of DNA to exclude non-specific amplification.
Single-strand conformation polymorphism (SSCP) analy-
sis was performed in an ABI 377 DNA Sequencer (PE-
Applied Biosystems) sequencing device using 4,25% non-
denaturing MDE polyacrylamide gels (Cambrex) at 20°C.
The gels were run under two different conditions, i.e.
standard MDE gel or with the addition of 5% glycerol to
the MDE gel. Automated DNA sequencing was performed
in part in the ABI 377 DNA Sequencer (PE-Applied Biosys-
tems), in part in an ALFExpress-2 DNA sequencer (Amer-
sham Life Sciences), using primers for routine PCR DNA
amplification. In the case of samples bearing the dele-
tions, PCR products were cloned into a commercially
available vector (TACLONE, Medigen, Novosibirsk) and
sequenced using universal and reverse primers.
Results
None of the 45 patients had the apoB R3500Q mutation,
whereas 25 patients had mutations in the LDL receptor
gene. Large genomic rearrangements in the LDL receptor
gene were previously shown to be an uncommon cause of
FH in St.-Petersburg [16] and had been excluded in most
patients of the current group. Therefore we restricted ourBMC Medical Genetics 2005, 6:6 http://www.biomedcentral.com/1471-2350/6/6
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Table 1: List of the LDL receptor gene mutations found in the current study
Mutation, systematic name Nucleotide 
change
Exon/Intron Rapid test 
method
Occurrence in other 
populations [7, 8]
Number of families 
(patients) with the 
mutation
Missense-mutations
C308Y c.985 G>A exon 7 FblI China 2 (2)
L380H (FH Pori) c.1202 T>A exon 9 MnlI Finland 1 (1)
D601N c.1864 G>A exon 13 EcoRV None (New) 1 (2)
C646S c.1999 T>A exon 14 SSCP None (New) 1 (1)
V776M c.2389 G>A exon 16 SSCP China (Hong-Kong), Cuba, 
South Africa (Afrikaners)
1 (2)
V806I (FH New York-5) c.2479 G>A exon 17 The Netherlands, USA 1 (1)
Nonsense-mutations
Q12X (FH Turkey/Milan-4) c.97 C>T exon 2 MaeI Italy, France, Turkey 1 (2)
E207X (FH Morocco) c.682 G>T exon 4 MaeI China, Germany, Korea, 
Morocco, Norway, Sweden, 
UK, USA
1 (2)
C249X c.810 C>A exon 5 DdeI, Fnu4HI None (New) 1 (1)
W422X c.1328 G>A exon 9 MaeI None (New) 2 (3)
Splice site mutations
IVS3+1G>A (FH-Elverum/ 
Olbia)
c.313+1G>A intron 3 SSCP Austria, Belgium, Denmark, 
Germany, Italy, Spain, Korea, 
Norway, The Netherlands, UK, 
Sweden, South Africa (black)
2 (3)
IVS9+1G>A c.1358+1G>A intron 9 AsuHPI The Netherlands 1 (1)
Frameshift mutations
FsK202: S205X c.670-671insG exon 4 SSCP None (New) 1 (2)
FsE287: V348X (FH North 
Karelia)
c.925-931del7 exon 6 SSCP Finland, Sweden, USA 1 (1)
FsE291: N309X c.936-940del5 exon 6 SSCP None (New) 1 (1)
FsV409: S423X c.1291-1331del41 exon 9 Sizing None (New) 1 (3)
FsE414: M429X c.1302delG exon 9 SSCP Germany 1 (1)
FsV597: A622X c.1855-1856insA exon 13 None (New) 1 (1)
In-frame deletions
G197del c.651-653del3 exon 4 HA UK 2 (2)
Neutral mutations
T705I (FH Paris-9) c.2177 C>T exon 15 Denmark, France, The 
Netherlands, UK, USA etc.
1 (1)
Silent mutations
P518P c.1617 C>T exon 11 None (New) 1 (1)
Footnote: HA – heteroduplex analysis; SSCP – single-strand conformation polymorphism analysis. Numeration of nucleotides and aminoacids 
follows Yamamoto's nomenclature [17] and the letter c. before the number of nucleotide indicates that it was taken from cDNA sequence.BMC Medical Genetics 2005, 6:6 http://www.biomedcentral.com/1471-2350/6/6
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search to point mutations and to minor deletions and
insertions. We identified 21 sequence variations (Table 1)
of which two probably were not pathogenic (in the fol-
lowing considerations we give numbering of aminoacids
in the LDL receptor according to Yamamoto's nomencla-
ture, [17] ). The T705I mutation (known also as FH Paris-
9) is not associated with elevated serum cholesterol [18],
and the transition c.1617C>T (P518P) is synonymous.
Table 2: Clinical features of St. Petersburg patients recruited for search of mutations in the LDL receptor gene
Patients 
ID
Sex Age TC, mg/dl TG, mg/dl LDLC, 
mg/dl
HDLC, 
mg/dl
Xanthomas/
Corneal 
arcus
CHD CI Mutation 
name
All exons 
sequencing
1 F 61 449 178 386 27 + + + V776M -
2 F 58 675 305 572 42 + + - T705I -
3 M 60 350 81 284 50 + + - FsV409: S423X -
4 F 49 326 203 248 37 - + - - -
5 F 36 414 201 321 53 + - - V806I -
6 M 68 404 192 333 33 + + - - -
7 F 76 522 161 444 46 - - - - -
8 F 54 446 165 353 60 - - - - -
9 F 52 500 ND ND ND - + + - -
10 F 62 370 120 303 43 + - - C308Y -
11 F 66 359 141 300 31 - + - - -
12 F 66 486 296 391 36 - + + Q12X -
13 F 52 469 228 389 34 + + - IVS9+1G>A -
14 F 53 325 101 286 19 - + + - -
15 F 58 446 192 334 74 - + - FsK202: S205X -
16 F 38 398 260 314 32 + - - FsE291: N309X -
17 M 46 280 117 220 37 - + + - -
18 F 58 519 179 446 37 - + - G197del -
19 F 54 364 135 300 37 + + + FsE287: V348X -
20 F 53 204 233 135 23 - + +++ - -
21 M 61 350 116 280 47 - - - - -
22 F 48 369 221 290 35 - + - - -
23 M 48 417 190 353 30 - + - C249X -
24 F 45 299 122 229 46 + - - IVS3+1G>A -
25 F 50 353 101 295 38 + - - FsE414: M429X -
26 F 45 558 210 478 38 + + + - -
27 M 62 469 136 398 44 + + ++ G197del +
28 F 8 915 179 850 29 + - - - +
29 F 40 367 73 283 69 - + - W422X +
30 F 60 480 104 393 66 - - - - +
31 M 41 314 247 226 39 - + + - +
32 M 37 344 292 262 24 + + + - +
33 F 52 360 744 179 32 + + + - +
34 M4 0 3 1 2 7 0 2 5 8 4 0 + + + + - +
35 M 29 253 79 195 42 - - - E207X +
36 M 38 520 168 447 39 + + + D601N +
37 F 19 447 156 362 54 - - - L380H +
38 F 63 347 84 266 64 + + + C646S +
39 F 56 432 106 374 37 + + - W422X +
40 M 47 540 226 446 49 + + + IVS3+1G>A +
41 F 70 433 123 370 38 - + + - +
42 M 34 534 ND ND ND + + + - +
43 F 52 654 115 573 58 + + + C308Y +
44 M 52 356 334 260 29 - + + - +
45 M 52 360 169 287 39 + + + FsV597: A622X +
Footnote: TC – total blood serum cholesterol, TG – triglycerides, LDLC – low density lipoprotein cholesterol, HDLC – high density lipoprotein 
cholesterol, CHD – coronary heart disease, CI – coronary infarction. Pluses in the CI column indicate number of CI survived. Minus in the right 
column indicates that the patient's LDL receptor gene was studied by high-sensitive fluorescent SSCP-analysis and not by frontal sequencing of all 
LDL receptor gene exons; the latter condition is indicated by plus.BMC Medical Genetics 2005, 6:6 http://www.biomedcentral.com/1471-2350/6/6
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We consider the remaining 19 variations to be patho-
genic. Eleven mutations have been described in other
populations, but to our knowledge the remaining 8 muta-
tions have not been described so far [7,8]. From two of
these nucleotide substitutions (C249X and W422X) the
stop codon arises, four are frame-shift mutations leading
to premature stop codons (FsK202:S205X;
FsK290:N309X; FsV409:S423X; FsV597:A622X), and two
result in amino acid substitutions (D601N and C646S).
Sequencing of the cloned mutant allele bearing the five-
nucleotide deletion (c.936-940del5 or FsE291) is demon-
strated on Fig. 1. Mutations c.313+1G>A, c.651-653del3,
C308Y and W422X were found in two probands each.
Rapid tests were developed for most of the mutations and
all of those were confirmed by using these methods (Table
1). Various detection methods, including heteroduplex
analysis, restriction enzyme tests and SSCP for several
mutations from the list are illustrated by Figures 2, 3.
Cosegregation of the mutations and elevated blood serum
cholesterol was demonstrated in seventeen families (see
Fig. 2, 3 and Table 1). Totally the mutations were con-
firmed in 9 relatives and excluded in 27 members of the
proband's families. Most important the diagnosis of FH
was excluded in 9 and set in 2 children of probands before
adulthood, i.e. prior to age 18. In these children mutation
detection was of crucial importance to set the diagnosis
and to suggest further life style.
In case of the Q12X mutation, the c.97C>T transition
leads to occurrence of a new Mae I restriction site (CTAG)
in exon 2 that allows a simple detection of this mutation.
Restriction enzyme test was performed for the proband
and her 4 descendants (Fig. 2). The presence of the muta-
tion was confirmed in the son of the proband and
excluded in the daughter and two grandchildren.
In some other mutations no restriction enzyme tests can
be developed for their rapid detection. For example, it is
true for the recurrent mutation IVS3+1G>A (c.313+1G>A)
that was identified by means of SSCP and verified by
sequencing in probands from two unrelated families.
SSCP patterns on silver-stained gels differ strikingly in
patients with and without the mutation. The presence of
the mutation was confirmed in the son of the proband by
SSCP.
Sequencing of the cloned mutant allele bearing the five nucle- otide deletion (c.936-940del5 or FsE291) Figure 1
Sequencing of the cloned mutant allele bearing the 
five nucleotide deletion (c.936-940del5 or FsE291). 
The sequence of the normal allele is shown at the top. The 
nucleotides absent in the mutant allele are underlined. The 
sequence of the mutant allele is shown at the bottom.
Detection of mutation Q12X in the LDL receptor gene by  means of Mae I restriction enzyme test Figure 2
Detection of mutation Q12X in the LDL receptor 
gene by means of Mae I restriction enzyme test. Tran-
sition c.97 C>T in exon 2 of the LDL receptor gene leads to 
appearance of the new Mae I restriction site (CTAG) in the 
patients with the mutation. Mae I restriction enzyme test 
enables to confirm the presence of mutation Q12X identified 
by DNA sequencing in the proband (12-1) and in her son 
(12-2) and to exclude presence of the mutation in other rela-
tives of the proband, including daughter (12-4) and grandchil-
dren (12-3 and 12-5). Lengths of DNA restriction fragment 
are given at the left in bp and *total blood serum cholesterol 
figures of the patients – at the bottom of the gel in mg/dl.BMC Medical Genetics 2005, 6:6 http://www.biomedcentral.com/1471-2350/6/6
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In heterozygotes a deletion of 41 nucleotides at c.1291-
1331 in exon 9 (mutation FsV409:S423X) results in occur-
rence of specific heteroduplexes. Besides, a PCR fragment
of smaller size as compared to the normal allele is
revealed in silver-stained polyacrylamide gels (Fig. 3).
This mutation was identified in the son and daughter of
the proband and excluded in the second daughter and in
her child (Fig. 3).
Discussion
Previously 13 mutations in the LDL receptor gene have
been reported in FH patients residing in St.-Petersburg
[12] (see Table 3). Eight of those have not been reported
in other populations. Our study revealed 21 mutations in
the LDL receptor gene, out of which only T705I was previ-
ously reported from St.-Petersburg [12]. Nineteen of those
21 mutations are likely to be pathogenic. We exclude
P518P (CCC>CCT; c.1617 C>T) from the list of patho-
genic mutations since the transition c.1617 C>T results
neither in an amino acid substitution nor in appearance
of the new consensus splicing sequences. P518P mutation
was found in the proband with mutation C646S, but it
was not clarified if the mutations were in cis- or trans-
position. Also we consider the T705I variant not to be a
primary cause of FH, since the I705 allele itself is not asso-
ciated with elevated cholesterol level [18] and the proba-
ble hypercholesterolemic effect of this mutation may be
due to its linkage with other pathogenic LDL receptor
gene mutations. Indeed, a variation in intron 7 (c.1061-
8T) of unclear functional significance was shown to be
very tightly linked to the I705 allele [19,20]. We have not
searched for this intronic variant in the LDL receptor in
the patient with the T705I substitution.
Among pathogenic mutations reported here, eleven have
been described in other populations (Table 1) [7,8], and
eight are novel. Six of the novel mutations lead to prema-
ture stop codons and result in truncated protein chains
that probably lose their function. One out of these trun-
cating mutations (c.936-940del5 or FsE291) also changes
invariant nucleotides nearby exon-intron junction and
thus may affect splicing. The D601N missense mutation,
causing substitution of aspartic acid by asparagine has not
been reported before. It seems likely that such a substitu-
tion might cause the loss of function since one other
mutation in the same codon (D601Y) was described in
familial hypercholesterolemia subjects [7]. The C646S
also has not been reported before, but 5 other mutations
affecting this codon have been described, one of which,
C646Y (FH French Canadian-2), results in a transport
defective protein (mutation class 2A) [21]. We, therefore,
find it very likely that the C646S mutation is also
pathogenic, but expression studies are needed to justify
the effect of both missense mutations D601N and C646S.
Previously described mutations were considered to be
pathogenic due mostly to their listing in FH mutation
databases even though functional studies were not sys-
tematically performed. Indeed, V806I mutation (known
as variant FH New York -5) [22] occurs in the LDL receptor
internalization signal NPVY, for which the consensus
sequence NPxY is given (where X is not a conserved
aminoacid) [23] and thus the substitution of isoleucin for
valine may be not crucial for the LDL receptor function.
The V776M mutation may have effect on LDL receptor
mRNA splicing rather than to be realized on the protein
level since the V776M mutation changes the invariant G
at the 3' end of exon 16. However, this mutation is likely
to be pathogenic since it was reported already in patients
from La Habana, Cuba [24].
Detection of mutation c.1291-1331del41 (mutation  FsV409:S423X) of the LDL receptor gene by means of PCR  product sizing and heteroduplex analysis Figure 3
Detection of mutation c.1291-1331del41 (mutation 
FsV409:S423X) of the LDL receptor gene by means 
of PCR product sizing and heteroduplex analysis. 
Deletion of 41 nucleotides results in significant change (indi-
cated by C) of molecular weight of the PCR-amplified LDL 
receptor gene exon 9 fragment and in formation of specific 
heteroduplexes (indicated by A). Letter B indicates the PCR 
product of normal size. Current gel supports the presence of 
c.1291-1331del41 mutation in two children (3-2, 3-3) of the 
proband (3-1) and absence of this mutation in his daughter 
and grandson (3–4, 3–5). *total blood serum cholesterol fig-
ures of the patients – at the bottom of the gel in mg/dl.BMC Medical Genetics 2005, 6:6 http://www.biomedcentral.com/1471-2350/6/6
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The apoB R3500Q mutation was not detected in any of
our patients. This finding is in agreement with the previ-
ous observation that the R3500Q mutation had not been
found in St.-Petersburg [25]. The mutation has been
detected in another part of Russia only in 2 of 71 patients
with symptoms of familial hypercholesterolemia [26].
The apoB R3500Q mutation is almost exclusively found
in Caucasian individuals, and almost all subjects with the
mutation carry the same haplotype. One of the highest
frequencies of the mutation has been found in the Swiss
population (approximately 1/200) [27], and Miserez and
Muller [27] hypothesized that the mutation may have
arisen in Switzerland 10,000 – 6,000 years ago. The prev-
alence of the mutation declines with increasing distance
from the Central Europe [27,28], and the prevalence of
the apoB R3500Q mutation is therefore expected to be
Table 3: List of the LDL receptor gene mutations reported previously from St. Petersburg, Russia [12 and References therein]
Mutation, 
systematic name
Nucleotide change Exon/Intron Rapid test method Occurrence in 
other populations 
[7, 8]
Number of families 
(patients) with the 
mutation
Large rearrangements
delta 5kb Large deletion exons 3-5 Southern blot None 1 (2)
Missense-mutations
C127W c.444 T>G exon 4 Mva I None 1 (1)
G128G, A130P [c.447 T>C; c.451 
G>C]
exon 4 Cac 8 I, Bsu R I None 1 (1)
C139G c.478 T>G exon 4 Msp I None 1 (3)
C146R c.499 T>C exon 4 Apa I None 1 (3)
C188Y c.626 G>A exon 4 Rsa I Czech Republic 1 (3)
G571E c.1775 G>A exon 12 SSCP Italy, Germany, 
Poland, Czech 
Republic, Austria, 
Belgium, Greece
1 (1)
Nonsense-mutations
C74X c.285 C>A exon 3 DdeI Korea, Northern 
Japan
1 (1)
E397X c.1252 C>T exon 9 Alu I None 1 (7)
In-frame deletions
347delGCC c.347-349del exon 4 HA, Fnu4HI None 1 (1)
G197del c.652-654del exon 4 HA Israel, USA, UK, 
Poland, Czech 
Republic, Germany, 
South Africa, The 
Netherlands
7 (14)
Neutral mutations
T705I (FH Paris-9) c.2177 C>T exon 15 Denmark, France, The 
Netherlands, UK, 
USA etc.
1 (1)
Silent mutations
H229H c.750 C>T exon 5 Nco I None (New) 1 (1)
Footnote: HA – heteroduplex analysis; SSCP – single-strand conformation polymorphism analysis. Numeration of nucleotides and aminoacids 
follows Yamamoto's nomenclature [17] and the letter c. before the number of nucleotide indicates that it was taken from cDNA sequence.BMC Medical Genetics 2005, 6:6 http://www.biomedcentral.com/1471-2350/6/6
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low in the St.-Petersburg area (< 1/1000). A precise esti-
mate would require a random sampling of the general
population.
Mutations in LDL receptor gene typical for various ethnic
groups were revealed in St.-Petersburg (Table 1). In partic-
ular, several mutations found in Denmark, Finland, Nor-
way and Sweden are present in the St.-Petersburg
population. The ethnic origin of these families is unclear
and according to questioning and family names no evi-
dence of a Scandinavian origin of probands was obtained.
Only exception from our previous FH group was the
proband with the E207X mutation who stated his German
roots and indeed this mutation was previously reported
from several families from Germany [29]. Interestingly,
no specific Slavic or Eastern-European founder mutations
were found in St.-Petersburg when comparing the LDL
receptor mutation spectrum of Russia to those of Poland
[10], Bulgaria [11] or Czech Republic [30,31]. G571E was
found in Russia, Czech Republic and Poland but this
mutation was also reported from many other countries
worldwide. The C188Y mutation found in Russia [32] and
in Czech Republic [30,31] cannot be considered a founder
Slavic mutation, since it was reported from unique fami-
lies in each country. Only one candidate for a Russian
founder mutation is C139G identified in four unrelated
families in different regions of the country, but this muta-
tion is absent in related nations of the Eastern Europe as
well as in other countries in the world.
In our study we were able to find LDL receptor gene path-
ogenic mutations in 23 of 45 patients. Many methods are
considered to be superior to routine isotopic SSCP when
screening for mutations in DNA (see e.g. [33]for compar-
ison of SSCP and DHPLC). However, we believe that
mutations could have been overlooked due to intrinsic
limitations of SSCP method in our hands only in few
cases. Fluorescent SSCP, used in the current study, can be
superior even to DHPLC and is a sensitive method for
mutation screening, especially when different gel electro-
phoresis conditions are applied [34]. Recent studies indi-
cate, that SSCP run under two different conditions detect
up to 96% of heterozygous variations (P.H. Nissen,
unpublished results). In our study LDL receptor gene
mutations were found in 56% (14 out of 26) patients
selected by SSCP and in 53% (10 out of 19) patients
which DNA was subjected to direct sequencing of all gene
exons (Table 2). We do not find it likely that many
patients are underdiagnosed due to presence of large
genomic rearrangements. In a study conducted in St.-
Petersburg, in the partly overlapping sample of FH
patients, only one case of a large deletion was found in the
sample of 50 probands, giving the rough estimate of
genomic rearrangements 2% [16]. In fact in mixed popu-
lations (such as that of that of St. Petersburg) the contri-
bution of large rearrangements to the spectrum of
pathogenic mutations seems to vary from 6% in Great
Britain [35] to 2.5% in English-speaking Canadians [36].
More important, some of intronic mutations leading to
defects of splicing could be missed, since the design of
primers [15] mostly following recommendations of
Hobbs et al. [22] with the only exclusion for primers to
amplify exon 3 allowed analyzing only 14 out of 34
intron-exon boundaries in the LDL receptor gene. Recent
investigation [37] demonstrated that a high percent of
previously missed LDL receptor mutations may be
localized in introns. In the cited study [37] in the patient
sample after modifying the gene analysis procedure nearly
27% of patients turned out to have intronic mutations,
despite the functional significance of these mutations
have still to be validated.
In the apoB gene we only looked for the R3500Q muta-
tion, and the possibility that other mutations in that gene
are responsible for hyperlipidemia cannot be ruled out.
This possibility is unlikely, since the apoB gene has been
studied extensively in other laboratories and no other
pathogenic variants have been determined. To conclude
we cannot definitely rule out the possibility that some
undiscovered mutations in the LDL receptor gene have
not been found. However, the possibility that the patients
have mutations in a different gene involved in FH still
remains since the mutation in the PCSK9 gene [3] were
not tested in this study.
With the two exceptions, mutations previously reported
from Russia [12,38] have been confined to a single family.
The exceptions were the mutations G197del (FH-Lithua-
nia), found in high percent of Ashkenazi Jewish families
with FH from St.-Petersburg [39], and the C139G muta-
tion found in two Slavic families from St.-Petersburg
[40,12], one family in Novosibirsk [38] and one family in
Moscow [41]. In this study 4 mutations, namely
c.313+1G>A, c.651-653del3, C308Y and W422X were
found in two unrelated families. Together with the previ-
ous findings we discovered 34 mutations in the LDL
receptor gene in St. Petersburg of which only six were
detected in more than one family. Fourteen LDL receptor
gene mutations were discovered by the other Russian FH
team from Moscow, Russia out of which only C139G is
shared with St.-Petersburg population [12,41]. To date a
total of 47 different FH mutations are known from Russia.
The data presented here enlarge the spectrum of muta-
tions found in the Russian population and make us regard
it as genetically heterogeneous.
Conclusions
We identified nineteen pathogenic mutations in the LDL
receptor gene in 23 probands and two probably neutral
mutations. In our study only four mutations in the LDLBMC Medical Genetics 2005, 6:6 http://www.biomedcentral.com/1471-2350/6/6
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receptor gene (c.313+1G>A, c.651-653del3, C308Y and
W422X) were found to be recurrent, i.e. all of those were
found in two apparently unrelated families. Together with
the data obtained earlier [12,38] our results present an
evidence against the strong founder effect among Russian
FH patients, and it is likely that in the St.-Petersburg area
there is as much genetic heterogeneity as in most other
areas of the world.
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